Abstract
Transmembrane protein 132 A (TMEM132A) has been recently reported to be a novel regulator of the Wnt signaling pathway, which is a cancer-associated cascade. However, the role of TMEM132A in cancer is not well characterized. Here, we used bioinformatics analysis to analyze the differential expression of TMEM132A in gastric cancer (GC) tissues and determine its diagnostic and prognostic value. Results showed that TMEM132A expression was upregulated in GC tissues. TMEM132A was also found to have diagnostic and prognostic roles in patient with GC. Furthermore, as evaluated by in vitro assays, knockdown of TMEM132A restrained cell proliferation, migration, and invasion of GC cells, while overexpression of TMEM132A exerted opposite effects. However, the effects of TMEM132A silencing and overexpression on GC cells were reversed by treatment with LiCl and ICG-001 (the Wnt signaling activator and inhibitor), respectively. In addition, in vivo assays showed that knockdown of TMEM132A suppressed GC tumorigenesis. Hence, our results provide new insights into the oncogenic role of TMEM132A in regulating GC cell proliferation, migration, and invasion, as well as its prognostic and therapeutic roles in patients with GC. These data highlight the diagnostic, prognostic, and therapeutic potential of TMEM132A in GC.
Author contributions
Qianqian Gao and Meihua Wang designed the research project. Qianqian Gao and Yufang Chen performed the experiments. Yufang Chen and Lingping Yue collected the data. Ziyan Li analyzed the data. Qianqian Gao drafted the manuscript. Meihua Wang revised and corrected the manuscript.
Disclosure statement
No potential conflict of interest was reported by the authors.
Data availability consent to publish
The data that support the findings of this study are available from the corresponding author, MH Wang, upon reasonable request.